Corvus Pharmaceuticals Inc — Liquidità (NASDAQ:CRVS)

Financials

Flusso di cassa derivante dalle attività operative -34.78 M-36.72 M-27.02 M-23.93 M-25.42 M-32.8 M -32.8 M Flussi di cassa derivanti dalle attività di investimento 44.77 M21.56 M-23.28 M15.54 M-27.48 M-7.8 M -7.8 M Liquidità derivante dalle attività di finanziamento 1.31 M62.16 M62.16 M7.86 M49.03 M36.43 M 36.43 M Liquidità libera -34.85 M-36.72 M-27.29 M-23.97 M-25.42 M-32.97 M -32.97 M

Notizie

Corvus Pharmaceuticals Stock: Strong Clinical Narrative, Already Priced For Success (CRVS)

Cantor Fitzgerald conferma il rating sul titolo Corvus Pharmaceuticals

Cantor Fitzgerald reiterates Corvus Pharmaceuticals stock rating

Oppenheimer raises Corvus Pharmaceuticals stock price target to $33

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

Corvus Pharmaceuticals in rialzo sui dati dello studio sulla dermatite atopica

Corvus Pharmaceuticals rises on atopic dermatitis trial data

Corvus Pharmaceuticals pubblica i risultati dopo dati positivi

Corvus Pharmaceuticals earnings on deck after positive trial data

Risultati Corvus in arrivo: il fermento sulla pipeline giustifica il rally?

Corvus earnings up next: Can pipeline buzz justify stock surge?

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 - Slideshow (NASDAQ:CRVS) 2026-01-27